TY - JOUR
T1 - The Pharmacogenetics of Efavirenz Metabolism in Children
T2 - The Potential Genetic and Medical Contributions to Child Development in the Context of Long-Term ARV Treatment
AU - Tan, Mei
AU - Bowers, Megan
AU - Thuma, Phil
AU - Grigorenko, Elena L.
N1 - Funding Information:
The preparation of this manuscript was supported by funding from R01 HD085836 from the National Institutes of Health (PI: Elena L. Grigorenko). Grantees undertaking such projects are encouraged to express freely their professional judgment. This article, therefore, does not necessarily represent the position or policies of the NIH and no official endorsement should be inferred.
Publisher Copyright:
© 2020 Wiley Periodicals, Inc.
PY - 2020/1/1
Y1 - 2020/1/1
N2 - Efavirenz (EFV) is a well-known, effective anti-retroviral drug long used in first-line treatment for children and adults with HIV and HIV/AIDS. Due to its narrow window of effective concentrations, between 1 and 4 μg/mL, and neurological side effects at supratherapeutic levels, several investigations into the pharmacokinetics of the drug and its genetic underpinnings have been carried out, primarily with adult samples. A number of studies, however, have examined the genetic influences on the metabolism of EFV in children. Their primary goal has been to shed light on issues of appropriate pediatric dosing, as well as the manifestation of neurotoxic effects of EFV in some children. Although EFV is currently being phased out of use for the treatment of both adults and children, we share this line of research to highlight an important aspect of medical treatment that is relevant to understanding the development of children diagnosed with HIV.
AB - Efavirenz (EFV) is a well-known, effective anti-retroviral drug long used in first-line treatment for children and adults with HIV and HIV/AIDS. Due to its narrow window of effective concentrations, between 1 and 4 μg/mL, and neurological side effects at supratherapeutic levels, several investigations into the pharmacokinetics of the drug and its genetic underpinnings have been carried out, primarily with adult samples. A number of studies, however, have examined the genetic influences on the metabolism of EFV in children. Their primary goal has been to shed light on issues of appropriate pediatric dosing, as well as the manifestation of neurotoxic effects of EFV in some children. Although EFV is currently being phased out of use for the treatment of both adults and children, we share this line of research to highlight an important aspect of medical treatment that is relevant to understanding the development of children diagnosed with HIV.
UR - http://www.scopus.com/inward/record.url?scp=85090028346&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090028346&partnerID=8YFLogxK
U2 - 10.1002/cad.20353
DO - 10.1002/cad.20353
M3 - Review article
C2 - 32657046
AN - SCOPUS:85090028346
SN - 1520-3247
VL - 2020
SP - 107
EP - 133
JO - New directions for child and adolescent development
JF - New directions for child and adolescent development
IS - 171
ER -